Payment overview · 2025
General Payments
$3,142.33
130 reported records · 31 companies
Healthcare provider profile · identity verified
Harmeet Sachdev, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SAN JOSE, CA · NPI 1023076361
Verified facts
What the public records show
CMS Open Payments records show Harmeet Sachdev, MD received $3,142.33 in general payments during 2025 across 130 reported records.
CATALYST PHARMACEUTICALS, INC. accounted for 12.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fycompa.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Fycompa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $387.02 | 12.3% | 21 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $301.14 | 9.6% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $223.04 | 7.1% | 10 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $214.48 | 6.8% | 8 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $205.49 | 6.5% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $197.84 | 6.3% | 12 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $164.07 | 5.2% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $160.53 | 5.1% | 7 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $114.62 | 3.6% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$107.78 | 3.4% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $102.79 | 3.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $98.88 | 3.1% | 4 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$79.17 | 2.5% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $78.47 | 2.5% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $74.24 | 2.4% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $73.29 | 2.3% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $69.25 | 2.2% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $62.57 | 2.0% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $54.87 | 1.8% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $52.78 | 1.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.16 | 1.6% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $42.20 | 1.3% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $35.28 | 1.1% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $33.27 | 1.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.79 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.09 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.85 | 0.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.80 | 0.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $22.62 | 0.7% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $16.58 | 0.5% | 1 | 2025 |
| Surgenex LLC | Unresolved — no canonical attribution shown | $14.37 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,130.96 | 129 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11.37 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $301.14 | 10 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $232.57 | 13 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $197.84 | 12 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $154.94 | 6 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $154.45 | 8 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $131.50 | 5 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $121.98 | 5 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $114.62 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $102.79 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $101.06 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $98.88 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $82.34 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $79.17 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $78.61 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $78.47 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $74.24 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $73.99 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $73.29 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $54.87 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $52.78 | 3 | 2025 |
Source payment records
|
|||||
| RYTARY Normalized: rytary |
Drug | Amneal Pharmaceuticals LLC | $42.20 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $33.27 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $33.13 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $32.79 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $26.34 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| FIBRYGA Normalized: fibryga |
Biological | Octapharma USA, Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| ArdeoGraft Normalized: ardeograft |
Biological | Surgenex LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| PelloGraft Normalized: pellograft |
Biological | Surgenex LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| RenoGraft Normalized: renograft |
Biological | Surgenex LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| SurGraft Normalized: surgraft |
Biological | Surgenex LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| SurMatrix Normalized: surmatrix |
Biological | Surgenex LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 149 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 42 |
| Gabapentin | Gabapentin | 119 | 42 |
| Lamotrigine | Lamotrigine | 79 | 22 |
| Levetiracetam | Levetiracetam | 74 | 20 |
| Lacosamide | Lacosamide | 71 | 16 |
| Donepezil Hcl | Donepezil Hcl | 41 | 12 |
| Glatiramer Acetate | Glatiramer Acetate | 40 | suppressed |
| Rivastigmine | Rivastigmine | 33 | 12 |
| Teriflunomide | Teriflunomide | 31 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 28 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Dalfampridine Er | Dalfampridine | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Copaxone | Glatiramer Acetate | 17 | suppressed |
| Fycompa | Perampanel | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,142.33 · 130 records | CATALYST PHARMACEUTICALS, INC. | ArdeoGraft, BOTOX, BRIUMVI, FIBRYGA, FIRDAPSE, FYCOMPA, Hizentra, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NURTEC ODT, Nayzilam, Ocrevus, Ocrevus Zunovo, PONVORY, PURIFIED CORTROPHIN GEL, PelloGraft, QULIPTA, REXULTI, RYTARY, RenoGraft, SKYCLARYS, SurGraft, SurMatrix, Symbravo, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYEPTI, WAKIX, ZAVZPRET, ZEPOSIA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fycompa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with CATALYST PHARMACEUTICALS, INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error